TW202233684A - 結合於葉酸受體α之重鏈抗體 - Google Patents

結合於葉酸受體α之重鏈抗體 Download PDF

Info

Publication number
TW202233684A
TW202233684A TW110142033A TW110142033A TW202233684A TW 202233684 A TW202233684 A TW 202233684A TW 110142033 A TW110142033 A TW 110142033A TW 110142033 A TW110142033 A TW 110142033A TW 202233684 A TW202233684 A TW 202233684A
Authority
TW
Taiwan
Prior art keywords
ser
seq
gly
val
sequence
Prior art date
Application number
TW110142033A
Other languages
English (en)
Chinese (zh)
Inventor
布萊恩 亞凡吉諾
凱瑟琳 哈里斯
哈尼斯 克姆
納森 特倫柯林
Original Assignee
美商泰尼歐生物公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商泰尼歐生物公司 filed Critical 美商泰尼歐生物公司
Publication of TW202233684A publication Critical patent/TW202233684A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110142033A 2020-11-18 2021-11-11 結合於葉酸受體α之重鏈抗體 TW202233684A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063115436P 2020-11-18 2020-11-18
US63/115,436 2020-11-18

Publications (1)

Publication Number Publication Date
TW202233684A true TW202233684A (zh) 2022-09-01

Family

ID=79024440

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110142033A TW202233684A (zh) 2020-11-18 2021-11-11 結合於葉酸受體α之重鏈抗體

Country Status (18)

Country Link
US (1) US20240002498A1 (https=)
EP (1) EP4247498A1 (https=)
JP (1) JP2023549851A (https=)
KR (1) KR20230110303A (https=)
CN (1) CN116615253A (https=)
AR (1) AR124084A1 (https=)
AU (1) AU2021383743A1 (https=)
CA (1) CA3199785A1 (https=)
CL (2) CL2023001432A1 (https=)
CO (1) CO2023006790A2 (https=)
CR (1) CR20230259A (https=)
IL (1) IL302670A (https=)
JO (1) JOP20230109A1 (https=)
MX (1) MX2023005693A (https=)
PE (1) PE20231203A1 (https=)
TW (1) TW202233684A (https=)
UY (1) UY39522A (https=)
WO (1) WO2022109010A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
CN111683966B (zh) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
WO2020206330A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2025252094A1 (zh) * 2024-06-05 2025-12-11 长春金赛药业有限责任公司 靶向叶酸受体α(FRα)的抗体、双特异性抗体和偶联物，及其制备和用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
KR101151957B1 (ko) 2004-07-22 2012-06-01 로저 킹돈 크레이그 결합 분자
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
PT3221356T (pt) * 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
EP4141032B1 (en) * 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
KR20250175345A (ko) 2016-06-21 2025-12-16 테네오바이오, 인코포레이티드 Cd3 결합 항체
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
AU2019236091B2 (en) * 2018-03-13 2025-06-05 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
WO2020206330A1 (en) * 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma

Also Published As

Publication number Publication date
IL302670A (en) 2023-07-01
US20240002498A1 (en) 2024-01-04
UY39522A (es) 2022-06-30
AU2021383743A9 (en) 2024-09-26
KR20230110303A (ko) 2023-07-21
CL2023001432A1 (es) 2024-01-05
CO2023006790A2 (es) 2023-06-09
CA3199785A1 (en) 2022-05-27
AR124084A1 (es) 2023-02-08
WO2022109010A1 (en) 2022-05-27
CN116615253A (zh) 2023-08-18
MX2023005693A (es) 2023-05-29
AU2021383743A1 (en) 2023-06-08
CL2025003126A1 (es) 2026-01-23
CR20230259A (es) 2023-07-13
JP2023549851A (ja) 2023-11-29
JOP20230109A1 (ar) 2023-05-18
EP4247498A1 (en) 2023-09-27
PE20231203A1 (es) 2023-08-17

Similar Documents

Publication Publication Date Title
JP7737488B2 (ja) Ｃｄ１９に結合する重鎖抗体
US20250236681A1 (en) Heavy chain antibodies binding to psma
TWI912972B (zh) 與ｃｄ２２及ｃｄ３結合之多特異性重鏈抗體
CA3176792C (en) Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions
TW202206462A (zh) 具有經修飾重鏈恆定區之多特異性重鏈抗體
TW202233684A (zh) 結合於葉酸受體α之重鏈抗體
CA3189297A1 (en) Multi-specific antibodies binding to bcma
JP2024507540A (ja) 抗ｐｓｍａ抗体及びｃａｒ－ｔ構造
KR20230171952A (ko) 항-cd20 항체 및 car-t 구조
RU2824170C2 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd19
EA053218B1 (ru) Антитела на основе тяжелых цепей, связывающиеся с альфа-рецептором фолата
JP2026071208A (ja) Ｂｃｍａに結合する多重特異性抗体
EA050239B1 (ru) Мультиспецифические антитела, связывающиеся с bcma
HK40100966A (zh) 与cd19结合的重链抗体
EA049498B1 (ru) Антитела к cd20 и car-t-клеточные структуры
HK40044275B (en) Heavy chain antibodies binding to cd19
HK40044275A (en) Heavy chain antibodies binding to cd19